A suite of bioassays to evaluate CREB inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Cyclic-AMP response element binding protein (CREB) is a nuclear transcription factor implicated in various cancer types.
• Overexpression and/or over-activation of CREB suggests its potential as a therapeutic target in oncology.
• Targeting CREB represents a novel strategy for developing new cancer therapies.

Purpose of the Study:

• To detail the development of small molecule inhibitors targeting CREB.
• To present biochemical and cell-based assays for evaluating CREB inhibitors.
• To highlight a potent CREB inhibitor with demonstrated in vivo anti-cancer activity.

Main Methods:

• Biochemical assays were employed to assess CREB inhibitor activity.
• Cell-based bioassays were utilized to evaluate the efficacy of small molecule CREB inhibitors.
• In vivo studies were conducted to determine anti-cancer effects.

Main Results:

• The study successfully developed the first cell-permeable small molecule inhibitor of CREB.
• A potent CREB inhibitor demonstrating in vivo anti-cancer activity was further developed.
• Biochemical and cell-based assays confirmed the efficacy of various small molecule CREB inhibitors.

Conclusions:

• Small molecule inhibition of CREB is a viable therapeutic strategy for cancer treatment.
• The developed CREB inhibitors show promise for in vivo anti-cancer applications.
• Further research into CREB inhibitors could lead to novel cancer therapies.